Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1068

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-Met和ALK抑制剂，在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂，其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1812.55	现货
5mg	RMB 900.49	现货
50mg	RMB 4681.47	现货
200mg	RMB 11687.8	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献334篇：

Cell, 2021, 184(10):2649-2664.e18

PubMed: 33848463 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )
Cancers (Basel), 2021, 13(16)4133

PubMed: 34439291 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0965.2020

PubMed: 34158345 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0221.2021

PubMed: 34158340 ( click the link to review the publication )

J Mol Biol, 2021, 433(19):167158

PubMed: 34273398 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1853-1864

PubMed: 33410241 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):25

PubMed: 33677467 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):27

PubMed: 33712563 ( click the link to review the publication )

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Biochem Pharmacol, 2021, 190:114620

PubMed: 34043966 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9011

PubMed: 33907223 ( click the link to review the publication )

Sci Rep, 2021, 11(1):12466

PubMed: 34127734 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9587

PubMed: 33953226 ( click the link to review the publication )

Mol Carcinog, 2021, 60(7):481-496

PubMed: 34018249 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

BMC Cancer, 2021, 21(1):310

PubMed: 33761896 ( click the link to review the publication )

Ann Hematol, 2021, 10.1007/s00277-020-04357-z

PubMed: 34110462 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, 53(7):823-836

PubMed: 33961012 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Angiogenesis, 2021, 10.1007/s10456-021-09771-z

PubMed: 33629198 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):78

PubMed: 34404896 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):60

PubMed: 34040000 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5704

PubMed: 33177525 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5017

PubMed: 33024122 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )
Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.1992.2020

PubMed: 33203698 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Front Immunol, 2020, 11:527750

PubMed: 33324391 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )
Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(14):2595-2611

PubMed: 32792859 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015891

PubMed: 33087447 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020,

PubMed: 32874131 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:2046248

PubMed: 33376716 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Oncogenesis, 2020, 9(7):64

PubMed: 32632141 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )
Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31072019 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )
Sci Rep, 2019, 9(1):19353

PubMed: 31852910 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(557)eaar5680

PubMed: 30459281 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )
Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28759046 ( click the link to review the publication )

Oncogene, 2017, 36(38):5407-5420

PubMed: 28534512 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )
Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27197184 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Elife, 2016, 5e12116

PubMed: 26987019 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(5):5646-63

PubMed: 26735175 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

PLoS Genet, 2015, 11(9):e1005533

PubMed: 26393505 ( click the link to review the publication )
Cancer Discov, 2015,

PubMed: 26432108 ( click the link to review the publication )

Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015,

PubMed: 25592111 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):122-32

PubMed: 25955731 ( click the link to review the publication )

BMC Cancer, 2015, 15:451

PubMed: 26036285 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31640-58

PubMed: 26436697 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )
Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26375439 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )
Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

PLoS Genet, 2013, 9(11):e1003958

PubMed: 24278035 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Clin Chem Lab Med, 2013, 51(9):1843-8

PubMed: 23612660 ( click the link to review the publication )
Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Oncotarget, 2013, 4(12):2237-48

PubMed: 24163262 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述

靶点

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞，作用于c-Met磷酸化作用时具有相似效果，IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞，具有相似的活性，且活力增高，IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时，IC50为13 nM。^[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时，与作用于野生型受体相比，效果发生显著改变，IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞，也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比，PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍，作用于IRK和Lck选择性高250多倍，作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反，PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值，为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型，和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长，IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡，IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵，IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射，IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活，和Matrigel入侵，IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。^[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞，也有效抑制 NPM-ALK磷酸化，IC50 为24 nM。PF-2341066 有效抑制细胞增殖，伴随着使细胞周期停在G(1)-S期，且诱导 ALK阳性的 ALCL 细胞凋亡，IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 ^[2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长 (例如,增殖和存活)和转移 (例如，入侵和形成克隆)。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL1	M{P2W2N6fG:2b4jpZ{BCe3OjeR?=				M1XRfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTEGgZ4VtdHNiZYjwdoV{e2mwZzDBUGsh[2:neIDy[ZN{cW6pIF7QUUB4cXSqIFnDOVAhd2ZiMD6wNUDPxE1?	NX;ZfVZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O\|I2QDlpPkKxOVczPTh7PD;hQi=>
BAF3	NXPOeldSS3m2b4TvfIlkKEG\|c3H5		MmK4OFghcA>?	MlXESG1UVw>?	NWP1UlFUS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IHPv[ZhxemW\|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAxNjZ{IN88US=>	MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3	NW\vbIpDS3m2b4TvfIlkKEG\|c3H5		NUT0TplHPDhiaB?=	NV7sUop1TE2VTx?=	MmX3R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDMNVE6Pk1ibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCyMlIh\|ryP	MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3	MXTDfZRwfG:6aXOgRZN{[Xl?		M{PPO\|Q5KGh?	NU\S[pdHTE2VTx?=	M3jPR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2=	M{Xz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
Kelly	NVT2R5VbS3m2b4TvfIlkKEG\|c3H5			M{nST2ROW09?	M3PWNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN	M13CRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
SH-SY5Y	MnrJR5l1d3SxeHnjJGF{e2G7			MXrEUXNQ	NFzXTIVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO	MnzZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
SMS-KCN	M3rBXWN6fG:2b4jpZ{BCe3OjeR?=			MV3EUXNQ	M3;OUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0>	M1vvRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
BAF3	MnfnR5l1d3SxeHnjJGF{e2G7		M364cFQ5KGh?	MULEUXNQ	M3H3XGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCWZXytRWxMKHerdHigTWM2OCCxZjCwMlE6KM7:TR?=	M3LrZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
3T3	M2W0fGZ2dmO2aX;uJGF{e2G7		M4LoXVEhcA>?	MUXEUXNQ	MUPJcohq[mm2aX;uJI9nKFKRTjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yODFOwG0>	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
3T3-E	NIHDelFHfW6ldHnvckBCe3OjeR?=		MWWxJIg>	NYX4Ood5TE2VTx?=	MVnJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO\|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=>	NHTBO289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
A549	MlTsT4lv[XOnIFHzd4F6		MmnxNUBp	M1uxNGROW09?	MYHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGNvTVXUJItqdmG\|ZTDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDIS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQCEQvF2=	NGT6PWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
BAF3-BCL	MUnGeY5kfGmxbjDBd5NigQ>?		MWGxJIg>	M1jyS2ROW09?	MkDiTY5pcWKrdHnvckBw\iCDQlygZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDFwMUW5JO69VQ>?	NXvjclBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
HEK293	M3ywdWZ2dmO2aX;uJGF{e2G7		MoHnNUBp	M3ztXGROW09?	MWHJcohq[mm2aX;uJI9nKEG[TDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUSg{txO	M3y4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
HEK293	NEjJbnNHfW6ldHnvckBCe3OjeR?=		MoG5NUBp	NXfFWWdjTE2VTx?=	NVL3NW5GUW6qaXLpeIlwdiCxZjDJVkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj64PFch\|ryP	MlPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
Jurkat	M1zIe2Z2dmO2aX;uJGF{e2G7		Mn:3NUBp	MV;EUXNQ	MXnJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
KARPAS299	MXXLbY5ie2ViQYPzZZk>		MXOxJIg>	NXnYdlVDTE2VTx?=	M2\NcWlvcGmkaYTpc44hd2ZiQVzLJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
PAE	NFLxemFHfW6ldHnvckBCe3OjeR?=		MUOxJIg>	NWCyZVBFTE2VTx?=	NFTxSZBKdmirYnn0bY9vKG:oIGTST2Ih[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuN\|k6KM7:TR?=	M3rCbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
PAE	M4fOXWZ2dmO2aX;uJGF{e2G7		NUfYZ3d5OSCq	NYXtSZZ4TE2VTx?=	NE[2WoxKdmirYnn0bY9vKG:oIGTST2Eh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuOVgh\|ryP	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
BAF3	NVrXcYxYTnWwY4Tpc44hSXO\|YYm=		NGO5fVEzNTNiZB?=	NULQRoJpTE2VTx?=	M1jhUWlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
BAF3	MWHGeY5kfGmxbjDBd5NigQ>?		Mn3KNk0{KGR?	MYHEUXNQ	MlH6TY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkG1NFgh\|ryP	M3\Ue\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SyNlUzLz5{M{e0NlI2OjxxYU6=
BAF3	MXzGeY5kfGmxbjDBd5NigQ>?		NWTYO3ZCOi1\|IHS=	NVr6bWJFTE2VTx?=	M1L2OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgNkB1dyB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5JJdqfGhiSVO1NEBw\iB\|LkS3PUDPxE1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2MkK1Nkc,OjN5NEKyOVI9N2F-
KARPAS299	M4fKemN6fG:2b4jpZ{BCe3OjeR?=		NGrIc4IzNTNiZB?=	MkmzSG1UVw>?	NUG3NlVuUUN3ME2wMlA3PDJizszN	M4nsNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{SyNlUzLz5{M{e0NlI2OjxxYU6=
EBC1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlrsO\|IhcA>?	MXfEUXNQ	MYLJR\|UxRTBwMEKzJO69VQ>?	NWW3NZlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
HCT116	NGLvc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX23NkBp	M373VGROW09?	NX7VXHBZUUN3ME2xOE45OiEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MCF7	M4PISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV23NkBp	MYTEUXNQ	MYPJR\|UxRTlwNUig{txO	MmLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
MDA-MB-231	NGPpfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MormO\|IhcA>?	NVzXOGl3TE2VTx?=	MVHJR\|UxRTFyLkig{txO	NHTKO4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
MKN45	M1jLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYO3NkBp	MW\EUXNQ	MWfJR\|UxRTBwMEGzJO69VQ>?	M3HMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
NCI-H441	NWewb4syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLwToo6PzJiaB?=	NXrQRmN2TE2VTx?=	NGjOellKSzVyPUG3MlI2KM7:TR?=	NWm3Rm1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
NCI-H661	NUHJcWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmLBO\|IhcA>?	MkPjSG1UVw>?	NYXycXI{UUN3ME2xNU41PyEQvF2=	M{HFTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
SK-MEL-28	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVO3NkBp	NEnRVZJFVVOR	Ml2yTWM2OD1zMD65O{DPxE1?	M3LuUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUmzN\|I5Lz5{M{m5N\|MzQDxxYU6=
SKOV3	NFq2ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2nIZlczKGh?	MUDEUXNQ	M1\DTmlEPTB;MUKuPFUh\|ryP	NEjGdmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
SNU5	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmrYO\|IhcA>?	NFr5fVRFVVOR	NHzYeXRKSzVyPUCuNFE3KM7:TR?=	NX7MT2JCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
Antiproliferative assay	M4DuUGVDSzF?		NF61[Is4OiCqcoO=		NUXoNFFKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIV5eHKnc4Ppcoch\WyndnH0[YQhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4ZTDjMW1mfCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yNUOg{txONg>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh4M{WyPUc,OjJ6NkO1Nlk9N2F-
Function assay	MVrLRXJRSVN{OUm=		NEjvXVI4OiCqcoO=		NUfYSllVUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR\|UxKD1iMD6wOlIh\|ryPLh?=	M{\xUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	NWPnUZdrVkmKLUPUNy=>		M3T0[\|EhcHJ?		M{TNfmlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBqdiCvb4Xz[UBPUUhvM2SzJINmdGy\|IHHzd4V{e2WmIHHzJJBpd3OyaH;yfYxifGWmIFHMT{Bt\X[nbDDh[pRmeiBzIHjyJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gNE4xQCEQvF2u	NHHad5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NHr5e5JPS0lvSEOxNlI>		M2LIWFczKGi{cx?=		NF7jb49KdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiCJbH:gZZN{[XluIFnDOVAhRSByLkGwPEDPxE1w	MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	MU\OR2kuUDJ{Mki=		M3zScVczKGi{cx?=		NXT1N5psUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh{MkK4JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR\|UxKD1iMD6xNVgh\|ryPLh?=	NGL1PI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NInYU5hPUUhvM2Sz		M1K4WFEhcHJ?		NHv1VmtKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNVY2KM7:TT6=	NEPlZYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	MXfOTWguO1R\|		NGjESnYyKGi{		MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwNEe4JO69VS5?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	M2D1Nm5KUC1\|VEO=		NEnyVVEyKGi{		NXzTcJBiUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlYxPSEQvF2u	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	NH\0V3ZPS0lvSEOxNlI>		NHLndlI4OiCqcoO=		NX;wd\|MzUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{IFfsc{Bie3OjeTygTWM2OCB;IECuOlI{KM7:TT6=	MmjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	MkC5UmlJNTOWMx?=		MWixJIhz		MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwNkK2JO69VS5?	MoLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	NYX1fXNEVkOLLVizNVIz		M3\Cc\|czKGi{cx?=		NHjTVGpKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BNOTF7Nl2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR\|UxKD1iMD64N\|gh\|ryPLh?=	NUjVb2xuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	NISwS2dPUUhvM2Sz		NIH2UmkyKGi{		MnnlTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLki0N{DPxE1w	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	M1ToSG5KUC1\|VEO=		M3LGSVEhcHJ?		NGDG[XpKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNFI3KM7:TT6=	M2LFeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	MmDKUmlJNTOWMx?=		NVrjXJNNOSCqch?=		NELNbphKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDDh[pRmeiBzIHjyJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gN{4xOzlizszNMi=>	NFqxV4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NH7wPWtDSUZ\|		M3fzT\|czKGi{cx?=		NWDnWlYxUW6qaXLpeIlwdiCxZjDOVG0wSUyNIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDbN2heNXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wOVEh\|ryPLh?=	NFfNd4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Function assay	M4TiUWJCTjN?		MWS3NkBpenN?		NUXIXFFuUW6qaXLpeIlwdiCxZjDOVG0wSUyNIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDbN2heNXSqeX3p[Ilv\SCrbnPvdpBwemG2aX;uJIF{e2G7LDDJR\|UxKD1iMD6wOVEh\|ryPLh?=	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2Nki2N\|IoRjJ2NE[4OlMzRC:jPh?=
Function assay	MXLCRWY{		NGfzOoE4OiCqcoO=		NVn2TFFrUW6qaXLpeIlwdiCxZjDOVG0wSUyNIFyxNVk3VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFt\|SG2teIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUCgQUAxNjJ4IN88UU4>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR4OE[zNkc,OjR2Nki2N\|I9N2F-
Cytotoxicity assay	MXjCRWY{		MXW3NkBpenN?		M13Qb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFt\|SG2teIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYYPzZZktKEmFNUCgQUAxNjl6IN88UU4>	NH\JWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Antiproliferative assay	MUTOTWgwO1R\|		Mm\QO\|IhcHK\|		NFvvUGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JINzcXqxdHnubYIuemW\|aYP0ZY51KG2xdYPlJG5KUC9\|VEOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNII\hdolidnRiMTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wPVU1KM7:TT6=	NXXhN2ZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O\|g2PDZ3PD;hQi=>
Antiproliferative assay	MkHKV3VRNU1{		MUC3NkBpenN?		M3\FPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIhiemKxcnnu[{BPWE1vQVzLJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE4PCEQvF2u	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NUS2OUc,OjR5OEW0OlU9N2F-
Antiproliferative assay	NW\mTJhiVkmKL{PUNy=>		MnjYO\|IhcHK\|		MlLRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDjdol7d3SrbnniMZJme2m\|dHHueEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyC4YYLpZY51KDFxTEGxPVZOKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE43ODZizszNMi=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6NUS2OUc,OjR5OEW0OlU9N2F-
Function assay	NFnOXpRPUUhvM2Sz		NXHZWXdvOSCqch?=		NH22R3FKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDoeY1idiCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQhcW5ibX;1d4UhVkmKLUPUN{Bk\WyuczDhd5Nme3OnZDDhd{BxcG:\|cHjvdplt[XSnZDDBUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFAvODhizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	MkSwUmlJNTOWMx?=		MlO4NUBpeg>?		NGqyZZJKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuNVY2KM7:TT6=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	NVTsZ2dWVkmKLUPUNy=>		MlH3NUBpeg>?		MlrzTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzOUGxOkc,OjR6MUmxNVY9N2F-
Function assay	MmjOUmlJNTOWMx?=		NYfrXmRNOSCqch?=		M1nQW2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS\|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD62NFUh\|ryPLh?=	MoXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
Function assay	MmjQUmlJNTOWMx?=		NEPRc4YyKGi{		MorwTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLk[yOkDPxE1w	M2rRV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NUn0UFV1VkmKLUPUNy=>		NVKxcHp7OSCqch?=		MlH4TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLki0N{DPxE1w	MoLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUmxNVYoRjJ2OEG5NVE3RC:jPh?=
Function assay	M{PLOG5KUC1\|VEO=		MVOxJIhz		M{DuPWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMT6wNlYh\|ryPLh?=	M3i4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	M4LGOW5KUC1\|VEO=		MXKxJIhz		NUTR[o9KUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCxMlE1QCEQvF2u	M{nEdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NXjROGxzVkmKLUPUNy=>		MVKxJIhz		NFnuSnNKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNTOWMzDj[YxteyCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDDh[pRmeiBzIHjyJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gN{4xOzlizszNMi=>	M1TyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NYHSc2YxVUuQOES1		M2nTWFEhcHJ?		NFzDUXRKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOU056NEWgZ4VtdHNiYX\0[ZIhOSCqcjDifUB4\XO2ZYLuJIJtd3S2aX7nMEBKSzVyIE2gNE4xOiEQvF2u	NWXmdFRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PTBpPkK0PVAxPzVyPD;hQi=>
Function assay	M3HuVm1MVjh2NR?=		M{\VTFkxKG2rboO=		NYnB[lBrUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUuQOES1JINmdGy\|IHHmeIVzKDlyIH3pcpMh[nliU3Hu[Jdq[2hvRVzJV2EtKEmFNUCgQUAxNjB{IN88UU4>	NFHPfWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc2OCd-MkS5NFA4PTB:L3G+
Function assay	MWDrZZJx[XNiMkm5		MlriPVAhdWmwcx?=		MYPJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIHvhdpBieyB{OUmgZ4VtdHNiYX\0[ZIhQTBibXnud{BjgSCVYX7ke4lkcC2HTFnTRUwhUUN3MDC9JFAvOTFizszNMi=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1NEc,OjR7MEC3OVA9N2F-
Cytotoxicity assay	NEH2ZWNPS0lvSEG5PVM>		M4H1PFQ5KGi{cx?=		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7OUOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwME[xJO69VS5?	NUH6dHhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
Cytotoxicity assay	NUK2bnBPVkmKL{PUNy=>		M{TuTFQ5KGi{cx?=		MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjN4NDFOwG0v	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
Cytotoxicity assay	NWi5bYpMSTV2OR?=		MV[0PEBpenN?		NUHLNXlSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPC5yOESg{txONg>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
Cytotoxicity assay	NEDhOnVPS0lvSEG5O\|U>		NYDhe5RLPDhiaILz		M{TjWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz61OVEh\|ryPLh?=	MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
Antiproliferative assay	MWHFRmMy		NWTiUFU1PzJiaILz		M{e3Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgZ21GXC2jbYDsbYZq\WRiaIXtZY4hTUKFMTDj[YxteyCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlAxPjlizszNMi=>	MmPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|EoRjJ2OUCwPFMyRC:jPh?=
Antiproliferative assay	NGDJOVRMSVKSQWOyPVk>		NVzvZ3pzPzJiaILz		NHjkeoVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUy2mZYDlcoRmdnRiaIXtZY4hU0GUUFHTNlk6KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMjFOwG0v	M4jaOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMyLz5{NEmwNFg{OTxxYU6=
Antitumor assay	NWHV[YN5SkGIMx?=	NUjsOJRUPTBibXevb4c>	NI\HcowzKHenZXvz		NUK3TWhQSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKG[3c3nvckBxem:2ZXnuJIFtdG:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhPTBibXevb4ctKHCxIIHkJIZweiB{IIfl[Yt{KHKnbHH0bZZmKHSxII\lbIlkdGVvdILlZZRm\CClb370do9t	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNUc,OjR7MEC4N\|E9N2F-
Antiproliferative assay	NVv5W41GTUKFMR?=		NF\TSWM4OiCqcoO=		MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjFizszNMi=>	M3HJc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUO3OVMxLz5{NUWzO\|U{ODxxYU6=
Antiproliferative assay	NFm3bYlUVlV3		MniyO\|IhcHK\|		NGjURY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPOWVUh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yMkC0JO69VS5?	NXzvbGg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OjNpPkK2NFA2PTJ\|PD;hQi=>
Antiproliferative assay	Ml:2SWJEOQ>?		NIfKd4g4OiCqcoO=		MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjF6IN88UU4>	NYTzO2U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFU2OjNpPkK2NFA2PTJ\|PD;hQi=>
Antiproliferative assay	M{faRm1MVjR3		NX\EcnEyPzJiaILz		MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2NTkS1JINmdGy\|IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODN6MTFOwG0v	M3PmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVI{Lz5{NkCwOVUzOzxxYU6=
Antiproliferative assay	NUDQdVFZSkGIMz;UVHIuVWW2		NEPGbXY4OiCqcoO=		MnK1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zM3RRWi2PZYSgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4yOjd2IN88UU4>	NEjLRok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	NXe2eXdOVkOLLVizNVIz		MVi3NkBpenN?		MkjuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDBUGsu\GWyZX7k[Y51KGi3bXHuJG5EUS2KM{GyNkBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ4MUKg{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5Nke0PUc,OjZ2N{[3OFk9N2F-
Antiproliferative assay	M4rxXG5EUS2KM{GyNi=>		NG\v[pQ4OiCqcoO=		Mn22RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjB\|MjFOwG0v	NFToZWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Function assay	MXTCZU9HOw>?		NXjiOJpGPzJiaILz		NW\BO3BlUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC2DTFugLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODV4IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	M1\4ZWJiN0Z\|		M1\PclczKGi{cx?=		M1fxPGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQuSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLhM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCwMlA2PiEQvF2u	NX3IOWR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	Ml3CRoEwTjN?		NHG3PW84OiCqcoO=		MWfJcohq[mm2aX;uJI9nKEWPTEStRWxMKFNzMkC2XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvODZ3IN88UU4>	NUL6bnloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	MVLCZU9HOw>?		NF3VWnY4OiCqcoO=		NEXxeJZKdmirYnn0bY9vKG:oIFXNUFQuSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEixJO69VS5?	Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	NHLFb2pD[S:IMx?=		MWW3NkBpenN?		NVzaOppNUW6qaXLpeIlwdiCxZjDFUWw1NUGOSzDDNVE2PllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkG0OEDPxE1w	Mlq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	M1j1OXNOWy2NQ17S		NUXzRYttPzJiaILz		NWPTN3hzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUXMuU0OQUjDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIGKxNlc2WSCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAxNjF5OTFOwG0v	NI[1bIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	M1yxPGtmdGy7		NGLNRpI4OiCqcoO=		M3voZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS3XscJkh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BHOTF5NFygcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6yNVEh\|ryPLh?=	M1XRUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MnfGUGFPPQ>?		NIHNbFc4OiCqcoO=		M{Pjb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTFHOOUBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJHIyOjd3UTDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSByLkKzNkDPxE1w	NH\jVZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	MVvESmNKPzZ?		NUTnUJJiPzJiaILz		M2S3OWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNlM{KM7:TT6=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	MoGyRoEwTjN?		MYW3NkBpenN?		MUDJcohq[mm2aX;uJI9nKEWPTEStRWxMKEdzMkCyVkBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvOzJ6IN88UU4>	M3;oXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MYXTT{1PNVOK		M37IVFczKGi{cx?=		M4\oR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1UUCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlM4KM7:TT6=	M1LiZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MmXMR2hNSTJy		NYr5VHpxPzJiaILz		NHr4cmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKFJzMke1VUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlQ{QSEQvF2u	NGrvXGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Function assay	Mlv6RoEwTjN?		NIPqdFQ4OiCqcoO=		NInXdHdKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFexNlY6SSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwNUGyJO69VS5?	M{LhXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MX;TTE1UYTW\		MWW3NkBpenN?		NFS4OmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPIMXN[PVliY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE42OjNizszNMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	MkfIRoEwTjN?		MWS3NkBpenN?		Mn3NTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCOMUG5Om0hdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjV2OTFOwG0v	NYfr[oZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	NU\WcFNVSmFxRkO=		NHPDcFc4OiCqcoO=		MoDiTY5pcWKrdHnvckBw\iCHTVy0MWFNUyCOMUG1NnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJiN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAxNjZ2NTFOwG0v	NX\zTW5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	MkPLV2suVi2ERTiyLS=>		MoDVO\|IhcHK\|		NX3uc2JvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUKHKEKpJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE44OSEQvF2u	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	Mm\LRoEwTjN?		MXG3NkBpenN?		MUHJcohq[mm2aX;uJI9nKEWPTEStRWxMKDFzNUHUbY5{KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC56NUeg{txONg>?	NH;oZ\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Cytotoxicity assay	M3fVTGJCN0Z\|		M3jjS\|czKGi{cx?=		MnTuR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFAvQTJ5IN88UU4>	M4\rVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	M1zwZmxCVjF?		NH21eo84OiCqcoO=		M{S4OmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTFHONUBk\WyuczDlfJBz\XO\|aX7nJGVOVDRvQVzLJGYyOTd2TDDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSBzLkO0OkDPxE1w	M{jLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	MUHTT{1PNU[L		NYHCS4x4PzJiaILz		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tSmkh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhTU2OND3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iTIXtbY5me2OnboSgR4VtdCCYaXHibYxqfHliQYPzZZktKEWFNUCgQUAyNjR4OTFOwG0v	NYr2OoJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	MnzJV2suVi2DUx?=		MnLDO\|IhcHK\|		NHvDeFlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uSVNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gUJVucW6nc3PlcpQhS2WubDDWbYFjcWyrdImgRZN{[XluIFXDOVAhRSBzLkS3N{DPxE1w	NHLidlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	NWm0S5dGTE[FSUGxOC=>		MWi3NkBpenN?		NEnjW2dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTGR2kyOTRiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCJMUK2PWEhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNU43OTVizszNMi=>	NHv1UlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	M4i0OmVDSzF?		MYK3NkBpenN?		NVfDW2p3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlAyQSEQvF2u	MluwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OUi1N\|YoRjJ4Nkm4OVM3RC:jPh?=
Cytotoxicity assay	MYTFRmMy		NHzhenU4OiCqcoO=		NELSZ2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6wOFQh\|ryPLh?=	NUjSUJRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVc2PDhpPkK3NFE4PTR6PD;hQi=>
Antiproliferative assay	NI\KZ5lMSVKSQWOyPVk>		MoexO\|IhcHK\|		NVH6UXJKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvOTB\|IN88UU4>	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay	MmjzV3VRNU1{		Ml;DO\|IhcHK\|		M{PIVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGxNkDPxE1w	M3m3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	Mlu0V3UuTEiOMR?=		NF3LNoo4OiCqcoO=		NF61[GFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVMWRJVDFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNVM3KM7:TT6=	MmHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay	NFywPW9PS0lvSEOxNlI>		MUm3NkBpenN?		NWDuXmZnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=>	M{nDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Function assay	M2[ydm5EUS2KM{GyNi=>		NH\hRmw4OiCqcoO=		NWGxPYU{UW6qaXLpeIlwdiCxZjDBUGsh\XiycnXzd4VlKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkK2NUDPxE1w	M12xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	M2HpXm5KUC9\|VEO=		MVm3NkBpenN?		M3XBTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViTlnIM\|NVOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG\|c3H5MEBKSzVyIE2gNE4zQDNizszNMi=>	NF7lV2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
Antiproliferative assay	NXzGZpE4VkmKL{PUNy=>		NGPCWmg4OiCqcoO=		NGDJdZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIF7JTE8{XDNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCOMUG5OkBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDFwMU[g{txONg>?	M1K1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxNFY3Lz5{N{GzNVA3PjxxYU6=
Antiproliferative assay	M1:1U2FNUy2yb4PpeIl3\SCNQWLQRXMzQTl?		MnfLO\|IhcHK\|		NWrlOZpsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBUGsueG:\|aYTpeoUhU0GUUFHTNlk6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKDl4IHHxeYVwfXNib37lJJNwdHW2aX;uJINmdGxicILvcIln\XKjdHnvckBie3OjeTygTWM2OCB;IECuN\|Y2KM7:TT6=	MlHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNES4N\|EoRjJ5MUS0PFMyRC:jPh?=
Antiproliferative assay	NXfwT2x5SUyNLX7l[4F1cX[nIGW5N\|c>		M4\QPVczKGi{cx?=		Ml2zRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDTFutcoVo[XSrdnWgWVk{PyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHlibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmeiB7NjDhdZVmd3W\|IH;u[UB{d2y3dHnvckBk\WyuIIDyc4xq\mW{YYTpc44h[XO\|YYmsJGlEPTBiPTCyMlI5PiEQvF2u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF2NEizNUc,OjdzNES4N\|E9N2F-
Cytotoxicity assay	MkXjTIVxTzJ?		MYi3NkBpenN?		MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55IN88UU4>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7NkmyPUc,Ojd\|OU[5Nlk9N2F-
Cytotoxicity assay	NYP6d29pVUmDUHHDZVI>		NX\rV2J1PzJiaILz		MnOyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWlCWGGFYUKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEeuNVYh\|ryPLh?=	NF3RV5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5OlkzQSd-MkezPVY6Ojl:L3G+
Cytotoxicity assay	MX\IR2M5Ojd?		Ml\DO\|IhcHK\|		M3XhSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz6yOUDPxE1w	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7NkmyPUc,Ojd\|OU[5Nlk9N2F-
Cytotoxicity assay	MknnT2FTWEGVMkm5		MYO3NkBpenN?		M{TL[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtCWlCDU{K5PUBk\WyuczDoZZJjd3KrbnegUnBONUGOSzDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC2PEDPxE1w	MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Cytotoxicity assay	MonPTGNEPzh?		NG\xbWQ4OiCqcoO=		NFn6SHNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS0N5ODDj[YxteyCqYYLic5JqdmdiU1zDN\|RCOi2UT2OxJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuN\|Qh\|ryPLh?=	NHjmd5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{S3OFkzPSd-Mke0O\|Q6OjV:L3G+
Antiproliferative assay	MXjTWU1FUExz		MkTCO\|IhcHK\|		NEL3enBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gV3UuTEiOMTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjB7MkOg{txONg>?	M121V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5OlI{Lz5{N{e2PVYzOzxxYU6=
Antiproliferative assay	NUXI[WhUVkOLLVizNVIz		MXW3NkBpenN?		NVOzZpZYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCVEtiY3;ud5RqfHW2aY\lcJkh[WO2aY\heIVlKGi3bXHuJG5EUS2KM{GyNkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJI9zKEOFS{igZZN{[XluIFnDOVAhRSByLkGwNFkh\|ryPLh?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OU[yN{c,Ojd5Nkm2NlM9N2F-
Antiproliferative assay	MUfLRXJRSVN{OUm=		NHXhXmM4OiCqcoO=		MnT6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDBUGsh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJIh2dWGwIFvBVnBCWzJ7OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjFyNEmg{txONg>?	MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5Nkm2NlMoRjJ5N{[5OlI{RC:jPh?=
Function assay	MWHOTWgwO1R\|				M3LxbWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9\|VEOgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	NIDCU3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MkTVUmlJNzOWMx?=				M3rUSGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9\|VEOgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	Mm\KUmlJNzOWMx?=				NWHXW5FpUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugSlEyPzSOIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC5zNkWg{txONg>?	NVPjUY5FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	M{jCUW5KUC9\|VEO=				M{XYNWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvOTZ3IN88UU4>	MmT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MXvOTWgwO1R\|				NVnoVpZxUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugR\|EyPT[\IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC52N{ig{txONg>?	NHjRPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NF;MVmJPUUhxM2Sz				NX\BNWY{UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugR\|EyPT[\IH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC52N{ig{txONg>?	M{HCXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	MXLOTWgwO1R\|				MkC0TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43ODVizszNMi=>	M1fSb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NXfNSmtDVkmKL{PUNy=>				NIrqNlZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZyNTFOwG0v	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MW\OTWgwO1R\|				M1zTU2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvPjJ4IN88UU4>	NGW4[Yg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NFPpbGhPUUhxM2Sz				M2Hkd2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvPjJ4IN88UU4>	M2jieFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	MWPOTWgwO1R\|				NVLZN\|N3UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC56NEOg{txONg>?	MnHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MlfrUmlJNzOWMx?=				M1eyVGlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVk3VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvQDR\|IN88UU4>	M2CzVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	MoOwUmlJNzOWMx?=				NG\H[JdKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDMNVE2OlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjB{NjFOwG0v	MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MoT2UmlJNzOWMx?=				M2XF[WlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVUzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFEvODJ4IN88UU4>	NU\Kcoo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	NY\jNHlIVkmKL{PUNy=>				NFrGbJpKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjF2ODFOwG0v	Moq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	M2LQVW5KUC9\|VEO=				MkfTTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyNFJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNU4yPDhizszNMi=>	M{DRTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NIjiNpBPUUhxM2Sz				NYPm[YI2UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugNVE2OVSrboOgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9\|VEOgZ4VtdHNuIFnDOVAhRSB\|LkCzPUDPxE1w	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	Mo\rUmlJNzOWMx?=				NGHDcppKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzCxNVUyXGmwczDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gUmlJNzOWMzDj[YxteyxiSVO1NEA:KDNwMEO5JO69VS5?	M1GwflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Cytotoxicity assay	NGTmSotGSkNz		Mn\GO\|IhcHK\|		Mn7DR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSWJEOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS2WubDDUbZRmei2JbH:gZZN{[XluIFHjeIl3cXS7IE2gNE4xOTNizszNMi=>	M{\2WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay	MXnNT241PQ>?		NIrwc2w4OiCqcoO=		NXXhW5gyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUuQNEWgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IFPlcIwhXGm2ZYKtS4xwKGG\|c3H5MEBC[3Srdnn0fUA:KDBwMEKyJO69VS5?	NXPWN5luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVU3OzVpPkK4O\|U2PjN3PD;hQi=>
Cytotoxicity assay	MkXNVGM{		M1P6XFczKGi{cx?=		NVL1VFhIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAzNjJ2NDFOwG0v	M3rPNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Function assay	MoLxRmFHOw>?		MkS4O\|IhcHK\|		MUDJcohq[mm2aX;uJI9nKEWPTESt[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	NFjCfpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	M13BOmJCTjN?		M37r[VczKGi{cx?=		NFK5UFNKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	NYjM[FlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	NY\STJFGSkGIMx?=		MWK3NkBpenN?		MkHyTY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiQVzLJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	M3i2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Antiproliferative assay	NHSy[o5PS0lvSEOxNlI>		MkTyO\|IhcHK\|		NIrVR4NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiRV3MOE1nfXOnZDDBUGshfmG{aXHuNUBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODN5IN88UU4>	MkK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	NU\aNIROVkOLLViyNlI5		MV[3NkBpenN?		MnHYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTESt[pV{\WRiQVzLJJZiemmjbkOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlA4OyEQvF2u	NYHRcnBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	MW\CRWY{		MVy3NkBpenN?		MlS0TY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiQVzLJGMyOTV4WTDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkG1JO69VS5?	NFLlT\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	M2K5eWJCTjN?		NXjS[nd1PzJiaILz		Ml7wTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDBUGshTjFzN{TMJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuN\|Ih\|ryPLh?=	M4DCRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Function assay	MX;CRWY{		M1\Xe\|czKGi{cx?=		MULJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCDTFugS\|EzODKUIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwNEOg{txONg>?	MmTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	NVW4c25pS0iO		NX7uSGoyPzJiaILz		NIC3VndCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNJVCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvPDVizszNMi=>	NWPucpByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	M17DNWJCTjN?		Ml\LO\|IhcHK\|		M1rX[2lvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD61PUDPxE1w	M4\SOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Antiproliferative assay	M4jMeWJCTjN?		M2HMO\|czKGi{cx?=		NYHE[oZOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNU4yKM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay	M{XBOWNJVw>?		MkixO\|IhcHK\|		NIrielBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNJVyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFMvOiEQvF2u	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay	NFLIZVFPS0lvSEKyNlg>		NX\jeHN[PzJiaILz		NUf2RnlbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ{MkigZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwNTFOwG0v	NFHXc\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC5NVQzPSd-MkmwPVE1OjV:L3G+
Antiproliferative assay	MULINlIzQC:FUh?=		NVTBbJlnPzJiaILz		MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh{MkK4M2NTKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxNEDPxE1w	MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOUG0NlUoRjJ7MEmxOFI2RC:jPh?=
Function assay	NH[2OZdJOjJ{OB?=	MmD4NE42KHWP	NWLKSJB[OyCqcoO=		NHO3fY9KdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBJOjJ{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IECuOUB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	MlXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOUG0NlUoRjJ7MEmxOFI2RC:jPh?=
Function assay	MlLqRoEwTjN?	M{Lx[FAvOSC2bzCxJJVO	NFn6RZQ4OiCqcoO=		MVvJcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2IH\1d4VlKEGOSzDlfJBz\XO\|ZXSgbY4hdW:3c3WgRoEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCCycn;sbYZmemG2aX;uJIF1KDBwMTD0c{AyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiN{KgbJJ{KG[xbHzve4VlKGK7IH3leIh6dC1\|SD30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiCvZXHzeZJm\CCjZoTldkA5KGi{czDifUBncWy2ZYKgd4NqdnSrbHzheIlwdiClb4XueIU>	NVHsT2ZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Antiproliferative assay	MV3LRXJRSVN{OUm=		M2\TOlczKGi{cx?=		M1LCXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB6NzFOwG0v	MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NFkoRjJ7MUe0PFA6RC:jPh?=
Antiproliferative assay	Mlm1TGNEPzh?		MlfsO\|IhcHK\|		NFe1d3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUeg{txONg>?	NH3zcYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
Antiproliferative assay	M1HTUW5EUS2KMkKyPC=>		M{jmVFczKGi{cx?=		Moi1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFIzOjhiY3XscJMhcGG{Yn;ybY5oKEWPTEStRWxMKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ2IN88UU4>	M3jCZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUe0PFA6Lz5{OUG3OFgxQTxxYU6=
Antiproliferative assay	NF7mS25PS0lvSEOxNlI>		M3HBOFQ5KGi{cx?=		M1Gze2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjhizszNMi=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5NEixOEc,OjlzN{S4NVQ9N2F-
Antiproliferative assay	MU\IR2M4QA>?		MWC0PEBpenN?		MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{IN88UU4>	NXj2WGptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5OTRpPkK5NVc1QDF2PD;hQi=>
Antiproliferative assay	NFHK[ZdGSkNz		MYK3NkBpenN?		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdoJtfWViYYPzZZktKEmFNUCgQUAxNjBzMzFOwG0v	NIrDVG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	Mn3PUWtPPDV?		MYS3NkBpenN?		NXPGUFlsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bi\nSncjC3NkBpenNiYomgRYxidWG{Ynz1[UBie3OjeTygTWM2OCB;IECuNFIzKM7:TT6=	NHm1WnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	NFHXW4VOS0Z5		NV[5Om1wPzJiaILz		NXj6cHRHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3ysJGlEPTBiPTCwMlA1PSEQvF2u	Mo[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	M2rNXWE2PDl?		MYm3NkBpenN?		NH;hZoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XlicnXsZZRqfmVidH:gZ49vfHKxbDygTWM2OCB;IECuNVM1OyEQvF2u	M1HCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	MVHIR3QyOTZ?		Mmr6O\|IhcHK\|		NF\2NpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgRYxidWG{Ynz1[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBKSzVyIE2gNE4zPTN4IN88UU4>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	M1LCWHNISzd7MEG=		NULyN5BMPzJiaILz		M4\leGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1fDO\|kxOSClZXzsd{Bi\nSncjC3NkBpenNiYomgRYxidWG{Ynz1[UBie3OjeTDy[YxifGm4ZTD0c{Bkd262cn;sMEBKSzVyIE2gNE4{OjF\|IN88UU4>	NWL0V\|NxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI1OTBpPkK5NlAzPDFyPD;hQi=>
Antiproliferative assay	NX:0bFhmVkOLLVi0OlA>		M1zMNVczKGi{cx?=		MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR\|UxKD1iMj6yOFQh\|ryPLh?=	NUP5WZB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI1OTBpPkK5NlAzPDFyPD;hQi=>
Antiproliferative assay	NWXhUoNZS0:OT{KwOS=>		NIX6[Xc4OiCqcoO=		M{C3bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1;MU\|IxPSClZXzsd{Bi\nSncjC3NkBpenNiYomgRYxidWG{Ynz1[UBie3OjeTygTWM2OCB;IEKuOFQ6KM7:TT6=	MnHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	M2HlbXBEOw>?		MnvsO\|IhcHK\|		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhSWyjbXHyZox2\SCjc4PhfUwhUUN3MDC9JFkvPzh5IN88UU4>	Mlu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	M17ZSmJCTjN?		NF;NU\|U4OiCqcoO=		MlmwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDDSFc1NVKRU{GgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBweiCFQ1u4JIF{e2G7LDDJR\|UxKD1iMD6wOFg3KM7:TT6=	M4THNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	M3;tTGJCTjN?		NX34[YgxPzJiaILz		MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMEW3OUDPxE1w	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	NUG5TXBCW1VvRFjMNS=>		MYS3NkBpenN?		MkW0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGwyKGOnbHzzJIhiemKxcnnu[{BPWE1vQVzLJIFnfGW{IEeyJIhzeyCkeTDTVmIhd3JiQ1PLPEBie3OjeTygTWM2OCB;IECuNVU2KM7:TT6=	Mnu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay	MXTLRXJRSVN{OUm=		NVi5Z5hMPzJiaILz		MkL0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMhcGG{Yn;ybY5oKE6STT3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4yPzZizszNMi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	M{PwRW5EUS2KM{GyNi=>		MUC3NkBpenN?		NFrBO4hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzF{MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjNyMzFOwG0v	NFzNeXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	NWnTcHFnSkGIMx?=		MkPWO\|IhcHK\|		NW[1fWc3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{BNOTF7Nl2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwM{Sg{txONg>?	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay	NF;ZOoJDSUZ\|		MVq3NkBpenN?		M3rIN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSW1NPC2DTFugS\|EzODKUIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjV4NDFOwG0v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	Mmm1RmFHOw>?		MoXuO\|IhcHK\|		NGHpRZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGNFPzRvUl;TNUBIOjB\|MmKgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwNUm0JO69VS5?	NVK1TYtWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	NWrTeZVsSkGIMx?=		MnPRO\|IhcHK\|		MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFnMN{1{fGmvdXzheIVlKG2xdYPlJGJCTjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE43PDRizszNMi=>	NYPuVWFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	NFuzfG9JS0N5OB?=		MX[3NkBpenN?		M3zKWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDO\|gh[2WubIOgbIFz[m:{aX7nJHNNSzN2QUKtVm9UOSCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjh6OTFOwG0v	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
qHTS assay	M2LGTXREOzJ?				NXvvc21yeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	M13SclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MWPBOlc{				MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NEXCVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	MUPTZY9{NTJ?				M362e5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NX;heYFyWkR?				MlTxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M2fNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NXy3ZWZbW0tvTj3TTC=>				NUj1boI4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MnHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M2jBUWJVNTF{				MoTEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	M3zBclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MWTNS{A3OyBqNj3US{BTMQ>?				Mnj1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NHfNOIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M{f6eG5DOTZ2Mx?=				NXTSeYVleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	MkHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MUXPTHMuPTB?				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NEHYVoRNSU5vNR?=				MlrQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUGFPNTViY3XscJM>	M{DreFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NHXMdoNPSi2HQnOx				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NXrWZ4ZyW0tvTj3TTC=>				MorrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M1HzXHJpPDF?				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MYHBOlc{				NVrKflN{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	NFe5TWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M4nvZ3JpOzB?				MkjEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	NXzhPXlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NVvZR4FmSlRvM{e=				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsdy=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	Mn;jUWchPjNiKE[tWGchWil?				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	NE\KbZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NXrq[mU2Wmh\|MB?=				NGrWS5dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	NHXKVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M{PTcW9JWy13MB?=				M2X2fJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>?	MljHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NF;w[FRUUi2JQl2y				MofLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M{nUU3NMNU5vTVO=				MmLmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M3TxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	Ml\xUmIuTUKlMR?=				NXnIVI4xeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M{m4NGxCVi13				Moq4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NULIe2xxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NUC1UoZRWmhzOB?=				M37mcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	M1HpelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MUnORlE3PDN?				NHXjWHdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	NHL3OpJUUy2QLV3D				MkjNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M360N3REOzJ?				NH3KUW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NVTGVFZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NFTsdYhTcDF6				NVHEO4pJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MmDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MYfTZY9{NTJ?				M{LEcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNid3NvMjDj[Yxtew>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Antiproliferative assay	NH7qeYNGSkNz		NHK0[4k4OiCqcoO=		NYL1cnZLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtKFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvODN7IN88UU4>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZyMkCzOkc,Ojl4MEKwN\|Y9N2F-
Function assay	MVvId\|U4QFR?	MoDDNVAxKG6P	M1LEeVMxKG2rboO=		MnXGTY5pcWKrdHnvckBw\iCqZYDzbY4udWWmaXH0[YQh[2:wdnXyd4lwdiCxZjDQdo8uUEeIIHnueI8h[WO2aY\lJIZwem1iaX6gbJVu[W5iSIO1O\|hVKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIF3FWEBxcG:\|cHjvdplt[XSrb36gZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgN\|AhdWmwczDmc4xtd3enZDDifUBz\WOxbXLpcoFvfCCqdX3hckBxem9vSFfGJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveEBu	M1Tj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Function assay	MnLWTGNEOTl\|Nx?=	MX[xNFAhdk1?	MUWzNEBucW6\|		MWDJcohq[mm2aX;uJI9nKGincIPpck1u\WSrYYTl[EBkd264ZYLzbY9vKG:oIGDyc{1JT0ZiaX70c{Bi[3SrdnWg[o9zdSCrbjDoeY1idiCKQ1OxPVM4KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIF3FWEBxcG:\|cHjvdplt[XSrb36gZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgN\|AhdWmwczDmc4xtd3enZDDifUBz\WOxbXLpcoFvfCCqdX3hckBxem9vSFfGJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgbY1ufW6xYnzveC=>	M1;nNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Antiproliferative assay	M4DTUm5EUS2KMkKyPC=>		NHrLRoY4OiCqcoO=		NF\PcmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOjJ{ODDj[YxteyCqYYLic5JqdmdiRV3MOE1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEi3JO69VS5?	M{PwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
Antiproliferative assay	M1fMWmhESzd6		M2LJfVczKGi{cx?=		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{e4JINmdGy\|IHjhdoJwemmwZzDTUGM{PEF{LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTdizszNMi=>	M1PJNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkKzNVIxLz5\|MEKyN\|EzODxxYU6=
Antiproliferative assay	MWrLRXJRSVN{OUm=		NIH6W\|Y4OiCqcoO=		Mnr4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXMzQTliY3XscJMhcGG{Yn;ybY5oKE6STT3BUGsh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjRizszNMi=>	NHHE[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKyN\|EzOCd-M{CyNlMyOjB:L3G+
NB1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVqyVXNVUUN3ME25NU46QCCwTR?=	MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-5	M3rMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3DZ5NKSzVyPUGwOU44PSCwTR?=	MmjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SR	NF\pSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPENWlKSzVyPUGyOk4{OSCwTR?=	NVq4TXE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SF539	NYruVox{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jG[WlEPTB;MkC0MlI1KG6P	NV\ueXY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SU-DHL-1	NVrMZpBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrOTWM2OD1\|M{[uPFIhdk1?	M4LMSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SCC-3	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\QbpRKSzVyPUO1Ok44PiCwTR?=	NWX5PVBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
DEL	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv2TnBKSzVyPUO2PU46KG6P	NEX4XmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CTV-1	M1X2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHlTWM2OD13OU[uOFghdk1?	NYfnPXFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EM-2	NHvNPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK5cYRKSzVyPU[wNU4{PCCwTR?=	Mlf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MHH-CALL-2	M4e3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;x[olKSzVyPU[4Nk42PyCwTR?=	MlHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KM12	NVWyb5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITOU4RKSzVyPUewOk46KG6P	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KINGS-1	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkKyTWM2OD15NEmuO\|Uhdk1?	M{jMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MEG-01	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jHT2lEPTB;OEW3MlY3KG6P	NX;VZZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
BV-173	M1XhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLpTWM2OD1zLkC1PVk4KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LAMA-84	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHyTWM2OD1zLkO4NlgzKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KARPAS-299	M{PqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrUWGRWUUN3ME2xMlQxQDZzIN88US=>	NV\LN\|dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
K-562	M4HXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFwN{KyOlkh\|ryP	NWTDN293RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-LMS-1	NGPRdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTFwN{[4Olch\|ryP	M4nHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MOLT-16	M2PyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PofmlEPTB;MT65OVU4PSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CMK	NHOzO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3LEV2lEPTB;MT65OlE2QSEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
ST486	NWjPcolQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPrXmFnUUN3ME2yMlQ{ODd\|IN88US=>	MnHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CI-1	M1q1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTEc5MxUUN3ME2yMlQ6PjV7IN88US=>	NIDI[FU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KP-N-RT-BM-1	M2nK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1S1TWlEPTB;Mj63NFEzOiEQvF2=	NGriVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ALL-PO	NITiWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLBc2RKSzVyPUOuNVgzODdizszN	NUjzZ2pHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KS-1	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTNwMkGyNlUh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
Becker	NV\mcYE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3QZpdsUUN3ME20MlI{QTNizszN	NIPORpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
GDM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfPV5dJUUN3ME20MlI1PjF5IN88US=>	M1TqWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
BC-1	M3Tsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X5WGlEPTB;ND60PVI4PyEQvF2=	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NB14	M1TROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnuU4xKSzVyPUSuPFM2OjRizszN	NH7LdYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NOS-1	NHvTUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELae4FKSzVyPUWuN\|M5PzRizszN	M4\1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MZ1-PC	M1LhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H1TGlEPTB;NT64NlE2OSEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
A498	NHPFS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPud2JKSzVyPU[uNFg1PzNizszN	MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
EW-16	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTZwM{e3O\|Mh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NALM-6	NFjVcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1:wNGlEPTB;Nj62PFM5PyEQvF2=	M3OxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
EB-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[3dYlKSzVyPUeuNFczOzNizszN	NFv1fFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
697	NU\VNI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS4TWM2OD17LkK0N\|I6KM7:TR?=	NWjYZ5E1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDUTWM2OD17LkW5PFQzKM7:TR?=	NW\2SpplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KNS-81-FD	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTlwNkm2OVMh\|ryP	M2\Vc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HUTU-80	NFrnUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlSyTWM2OD17Lke0OlQzKM7:TR?=	NHi1RXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LS-411N	NX7KT5A1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPtTWM2OD1zMD6wOVY4KM7:TR?=	NWrvR3BGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
RPMI-8402	NHeze\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PlTmlEPTB;MUCuNVE3KM7:TR?=	Ml;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KU812	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFyLkK5PVEh\|ryP	Moq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
EW-1	M1\DWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUf0bppiUUN3ME2xNE41PDJ3IN88US=>	NFjXW2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
HC-1	MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1H1e2lEPTB;MUCuOFg1PCEQvF2=	M3XSc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NB69	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzidmxvUUN3ME2xNE42ODR\|IN88US=>	NUn5fIhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MFH-ino	NX\0VHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjmTWM2OD1zMD64N\|A{KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CCRF-CEM	NVT1S49NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XEV2lEPTB;MUGuOVk4KM7:TR?=	NFTnSmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SK-N-DZ	NWXWVpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF{LkC0N\|Yh\|ryP	M3jofFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-H720	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j3RmlEPTB;MUKuNVcxPSEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HCC1187	NFvXO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzuZmFKSzVyPUGyMlIxPDFizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
IST-SL2	NHrzN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\PR5ZKSzVyPUGyMlQ5PzJizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KE-37	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzXfIVKSzVyPUGyMlc6PjZizszN	NYH0c21ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HCC1599	NYPBOmZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHWXXByUUN3ME2xNk46ODZ7IN88US=>	NVfwNHdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A4-Fuk	NHjXeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLrOGFIUUN3ME2xNk46PTh4IN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NKM-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjwVm0{UUN3ME2xN{4zQTJ3IN88US=>	MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
BE-13	NF:3UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYewVYU3UUN3ME2xN{44QTh7IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MV-4-11	NHfXVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vWTGlEPTB;MUSuNFMzPCEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
OPM-2	M2jIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmC0TWM2OD1zND60NFg2KM7:TR?=	MmfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KARPAS-422	M2C0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF2LkWxNlYh\|ryP	NFexW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
RPMI-8226	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrwTWM2OD1zND64PVE2KM7:TR?=	MkS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KARPAS-45	M2LWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF3Lke3NVYh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-PN-DW	M2XNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnmeGhYUUN3ME2xOU45PjNzIN88US=>	M2fEOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LC-2	NFf6UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF4LkG1NFYh\|ryP	NEXq[pY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NCI-H1648	NGW4cJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rqd2lEPTB;MU[uNlU1KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
RL95-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF4LkO5O\|gh\|ryP	MnnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KNS-42	M3nkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\wWmlEPTB;MU[uO\|I4PCEQvF2=	MlrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
RPMI-6666	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLNTWM2OD1zNj65NlEyKM7:TR?=	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SIG-M5	MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUn0bY12UUN3ME2xO{4yQTB\|IN88US=>	Mn;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NHqySXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmf2TWM2OD1zNz63OFUyKM7:TR?=	NEG0XZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MONO-MAC-6	NIfZ[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2C5emlEPTB;MUeuPVMyOiEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LAN-6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF6Lke1OVch\|ryP	NHfISGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
A388	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfyb45RUUN3ME2xPU4{ODV7IN88US=>	M{T2Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SK-NEP-1	NGfMbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUixfG9SUUN3ME2yNE4zOTN{IN88US=>	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
TE-10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz3TWM2OD1{MD61NlIyKM7:TR?=	NEDr[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
HL-60	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{W1V2lEPTB;MkCuPVA6QSEQvF2=	MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MC116	MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLiTWM2OD1{MT63NlIyKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SW962	M{XFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3wTph5UUN3ME2yNU44QTF3IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NOMO-1	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf5TWM2OD1{Mj62OVY1KM7:TR?=	NYHMfJJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CTB-1	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkn5TWM2OD1{Mj64OlcyKM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3QdIdNUUN3ME2yNk46ODd2IN88US=>	NH3jdZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
GR-ST	M2HyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTkTWM2OD1{Mz63OkDPxE1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HH	MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXwOpJKSzVyPUK0MlAxOyEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H1963	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TQfGlEPTB;MkSuNFc5OiEQvF2=	M3;5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
QIMR-WIL	NFG0e2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlG3TWM2OD1{ND64O\|czKM7:TR?=	NFjKW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CGTH-W-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfRd3o3UUN3ME2yOU4xPzJ\|IN88US=>	NYOzfFRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LP-1	NXnPbFA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r3b2lEPTB;MkWuOlU2OSEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H748	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPYcJlKSzVyPUK2MlUyOzdizszN	NHrJN4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
PF-382	NXrvN5FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXkR5ZoUUN3ME2yO{4zOjJ\|IN88US=>	MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ATN-1	NUjzTZZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLuTWM2OD1{Nz6zO\|MzKM7:TR?=	M4rnZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
L-540	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\DTWM2OD1{Nz62OFU6KM7:TR?=	NUjOW3ZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LXF-289	NG[2W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJ5Lke1NVkh\|ryP	NHXIS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LS-513	NVLzeJZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rlVWlEPTB;MkiuNVgxPyEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H1581	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;EOmlEPTB;M{CuN\|k4PiEQvF2=	M{jCNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ES6	M1XheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nxV2lEPTB;M{CuOlg6QSEQvF2=	M1q0d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW982	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjPTWM2OD1\|MD64OVY3KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
DOHH-2	M4LMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETt[GVKSzVyPUOxMlU5QTNizszN	M2jyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DB	M1:0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTN\|Lkm0N\|Eh\|ryP	MkTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MPP-89	M2K0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTN2LkG3OVYh\|ryP	NIeyZ5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
LB831-BLC	M3\jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzvTWM2OD1\|ND61NVg1KM7:TR?=	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NB5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\5[GlEPTB;M{SuPFU{PSEQvF2=	MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
GB-1	M2HUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm5[FF7UUN3ME2zOU4xPDZ7IN88US=>	NF62ZpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
TE-15	Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M320ZWlEPTB;M{WuNlI{QCEQvF2=	NUH5fHNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LC4-1	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTN3LkO4OFch\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H747	NIi0WW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTN4LkGzOlkh\|ryP	NYn3S4VmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	NGXk[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvLTWM2OD1\|OD63N\|Q4KM7:TR?=	NXv0cWxnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-MM-2	NXvjfmp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzW[oVkUUN3ME20NE4yOTR4IN88US=>	NETVXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
TGW	NGfWc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLQfHNsUUN3ME20NU4xPTZ\|IN88US=>	NIXmNFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ONS-76	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHm4PZlKSzVyPUSyMlQ5QDNizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CPC-N	NXvsbXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXuZ3JKSzVyPUSyMlk6PzFizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
ES4	NFHFOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;rOoR7UUN3ME20OE41OTV\|IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
Daudi	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHWOHVKSzVyPUS1MlA5OjdizszN	NYDWPIZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MOLT-4	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnETWM2OD12NT6wPFU{KM7:TR?=	M1\2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HT-144	NYTMPYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz3PIpKSzVyPUS2MlczPiEQvF2=	MnvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SW872	M1vtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7oOFY5UUN3ME20PE4yQTN\|IN88US=>	Mn\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
D-283MED	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTR6LkO1OFIh\|ryP	Ml3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H2126	NFW4d2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF6yR4NKSzVyPUS4Mlg1PzZizszN	MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-SNU-16	NXmzWZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT6SFVqUUN3ME20PU4zOTR\|IN88US=>	NFS3dmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
CESS	M2D4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH4TWM2OD12OT61NFg5KM7:TR?=	M{DTcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
A101D	NUTvTWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHGNGZKSzVyPUS5Mlk4OzZizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm³) 明显衰退，且按43天处理日程处理后，平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上，完全抑制GTL-16肿瘤生长，PF-2341066每天按50 mg/kg剂量处理小鼠，3个月后，只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天，观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型，处理周期为33天，观察到平均肿瘤体积降低53%，且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长，在实验最后一天，抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型，不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤，观察到CD31阳性内皮细胞显著降低，这种作用存在剂量依赖性，说明 MVD 受抑制，且具有相关的抗癌高效性，这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型，显著降低人VEGFA 和IL-8血浆水平，这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤，观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。^[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠，具有抗癌高效性，这种作用存在剂量依赖性，处理15天，所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器，及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂，这些与 NPM-ALK 磷酸化和功能受抑制相关。^[2] PF-2341066 抑制骨肉瘤的一些活动行为，及其肿瘤生长(例如, 增殖和存活)和转移 (例如，入侵和形成克隆)。PF-2341066口服饲喂裸鼠，抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。^[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤，引起肿瘤衰退，这与¹⁸F-FDG 摄取的缓慢降低相关，且降低葡糖糖转运蛋白 1, GLUT-1的表达。^[4]

激酶实验： ^[1]	- 合并生化激酶实验: 使用连续耦合的分光光度测定c-Met催化活性，通过分析NADH消耗率而测定c-Met诱导的ADP产量，这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定K_i值, 在含实验试剂的实验孔中加入不同浓度PF-2341066，然后在37^oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验： ^[1]	- 合并 Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞 Concentrations: 0 nM-256 nM Incubation Time: 1小时 Method: GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上，孔中含培养基，培养基中含10% 胎牛血清(FBS)，然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)]，处理 24小时。在调查配体依赖的RTK 磷酸化实验中，加入相应的生长因子，处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时，然后使用含 1 mmol/L Na₃VO₄的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化，使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时，在4^oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸（PY-20）抗体（1:500）中温育20分钟;(d) 再次冲洗7次;(e)在3,3^′,5,5^′-四甲基联苯胺过氧化物酶底物中温育，开始显示反应，加入0.09 N H₂SO₄终止反应; (f)在450 nm 处使用分光光度计测定吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day Administration: 口服处理 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+dd H2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Crizotinib (PF-02341066) SDF

分子量	450.34
化学式	C₂₁H₂₂Cl₂FN₅O
CAS号	877399-52-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Not Applicable
NCT03947385	Recruiting	Drug: IDE196\|Drug: Binimetinib\|Drug: Crizotinib	Metastatic Uveal Melanoma\|Cutaneous Melanoma\|Colorectal Cancer\|Other Solid Tumors	IDEAYA Biosciences	June 28 2019	Phase 1\|Phase 2
NCT03439215	Active not recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical research technology Srl	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Active not recruiting	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
回答：
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

选择性强的c-Met抑制剂

PF-04217903 : C-Met-selective, IC50=4.8 nM.
活性最高的c-Met抑制剂

INCB28060 : C-Met, IC50=0.13 nM.
用于临床的c-Met抑制剂

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.
最新的c-Met抑制剂

EMD 1214063 ^New : Potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

研究领域

产品类型

定制您的化合物库

Crizotinib (PF-02341066)

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献334篇：

产品安全说明书

c-Met抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Crizotinib (PF-02341066) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

常见问题及建议解决方法

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品